RxDoctor Payments Data

Hasan Syed, DO

Endocrinology, Diabetes & Metabolism · Skokie, ILNPI 1881170322

Payments from drug & device makers

$1,320in general payments, 2019–2025

Across 21 payments — averaging $62.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tandem Diabetes Care, Inc.$243
  • Mannkind Corporation$195
  • Abbott$147
  • Amgen$145
  • Lilly USA, LLC$140
  • Dexcom, Inc.$128
  • plus $323 from 5 others

What the payments were for

  • Food & beverage$1,15087%
  • Education$12810%
  • Gifts$433%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,320 in reported general payments places this provider in the 55th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.

See all endocrinology, diabetes & metabolism providers in Illinois

Medicare billing

Part B allowed, 2024
$63,138
Medicare patients
274
Services billed
623

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide52$72,308
JardianceEmpagliflozin42$55,611
RybelsusSemaglutide23$26,738
OzempicSemaglutide23$25,034
TrulicityDulaglutide18$21,285
TradjentaLinagliptin18$17,441
Tresiba Flextouch U-100Insulin Degludec13$6,464
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$5,036
Humalog Kwikpen U-100Insulin Lispro14$4,545
Novolog FlexpenInsulin Aspart16$3,796
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$1,186
Metformin Hcl ErMetformin Hcl38$832
Levothyroxine Sodium85$767
Hydrocortisone17$684
Alendronate Sodium30$211

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$140$93,59370 claims
Novo NordiskRybelsus, Ozempic$12$51,77346 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.

Other endocrinology, diabetes & metabolism in Skokie

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →